15 Administered subcutaneously and intravenously. Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 23 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF-STUDY CRITERIA Prior to removal from study, effo rt must be made to have all subjects complete a safety visit approximately 30 days following t he first follow- up evaluation on Day 56. 3.6.1 Criteria for Removal from Protocol Therapy Patients will be taken off tr eatment for the following: xCompletion of treatment xGrade 3 or 4 toxicity due to the vaccine, excluding those known events such as local injection site reactions, skin r ash, pruritus, fatigue, fever a nd local adenopathy. xProgression of disease xParticipant requests to be w ithdrawn from active therapy xInvestigator discretion xPositive pregnancy test 3.6.2 Off-Study CriteriaPatients will be taken off study for the following: xCells do not meet CoA requirements xCompleted study follow-up period xPatient requests to be withdrawn from the study xThere is significant noncompliance xLost to follow-up xInvestigator discretion xProgression of disease xDeath All patients will be co-enrolled on the NCI SB companion protoc ol, 09-C-0161 (Follow up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies). Patients who are taken off-study for progressive di sease or study closure on the treatment protocol may be followed on protocol 09-C-0161.Once a patient is taken off study, no further data can be collec ted. 3.6.3 Off Protocol Therapy and Off-Study ProcedureAuthorized staff must notify the Central Registration Office (C RO) when a subject is taken off protocol therapy and when a subj ect is taken off-study. A Parti cipant Status Updates Form from the web site ( http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be completed and sent via encrypted e mail to: NCI Central Registrat ion Office at ncicentralregistration-l@mail.nih.gov.4 CONCOMITANT MEDICATIONS/MEASURESOver the counter medications, such as ibuprofen, may be used to provide relief of local injection site reactions. Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 245 BIOSPECIMEN COLLECTION Blood and tissue are tracked at th e patient level and can be li nked to all protocols on which the patient has been enrolled. Sam ples will be used to support the specific objectives listed in the treatment protocol(s), e.g., imm unologic monitoring, cytokine l evels, persistenc e. Patients who agree to have specimens and data stored to support long-term research efforts within the NCI SB will be consented and enrolled on 03-C-0277. The amount of blood that may be drawn from adult patients for r esearch purposes shall not exceed 10.5 mL/kg or 550 mL, whichever is smaller, over any eight-week period. Samples will be ordere d in CRIS and tracked through Clinical Tr ial Data Management system.